New developments in medical clinical trials

Journal of Dental Research

Volumn 83, Issue SPEC. ISS. C, 2004, Pages

  D'Agostino Sr , R B ^a,b   Massaro, J M ^a,b  

^a BOSTON UNIVERSITY   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Study analysis; Study conduct; Study design

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; METHODOLOGY; MULTICENTER STUDY; PROFESSIONAL STANDARD; RANDOMIZED CONTROLLED TRIAL; REVIEW;

CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; CONTROLLED CLINICAL TRIALS; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 4143150945     PISSN: 00220345     EISSN: None     Source Type: Journal    
DOI: 10.1177/154405910408301S04     Document Type: Conference Paper

References (47)

1. Albert PS (1999). Longitudinal data analysis (repeated measures) in clinical trials. Stat Med 18;1707-1732.
2. Armitage P (1999a). Data and safety monitoring in the Concorde and Alpha trials. Controlled Clin Trials 20:207-228.
3. Armitage P (1999b). Data and safety monitoring in the Delta trials. Controlled Clin Trials 20:229-241.
4. Armstrong PW, Furberg CD (1995). Clinical trial data and safety monitoring boards. The search for a constitution. Circulation 91:901-904.
5. Blackwelder WC (1982). Proving the null hypothesis. Controlled Clin Trials 3:345-353.
6. Burton P, Gurin L, Sly P (1998). Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equation techniques and multi-level mixed modeling. Stat Med 17:1261-1291.
7. Buyse M, Molenberghs G (1998). Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54:1014-1029.
8. Chuang-Stein C, Le V, Chen W (2001). Recent advances in the analysis and presentation of safety data. J Drug Inform Assoc 35:377-397.
9. Cnaan A, Laird NM, Slasor P (1997). Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 16:2349-2380.
10. D'Agostino RB Jr (2000). The slippery slope of surrogate outcomes (debate). Curr Control Trials Cardiol 2:76-78.
11. D'Agostino RB Sr (2000). Controlling alpha in a clinical trial: the case for secondary endpoints (editorial). Stat Med 19:763-766.
12. D'Agostino RB, Heeren TC (1991). Multiple comparisons in over-the-counter drug clinical trials with both positive and placebo controls. Stat Med 10:1-6.
13. DeMets DL, Lan KKG (1994). Interim analysis: the alpha spending function approach. Stat Med 13:1341-1352.
14. Diggle PJ, Liang KY, Zeger SL (1996). Analysis of longitudinal data. Oxford: Oxford University Press.
15. Ebbutt AF, Frith L (1998). Practical issues in equivalency trials. Stat Med 17:1691-1701.
16. Ellenberg JH (1996). Intent-to-treat versus as-treated analysis. J Drug Inform Assoc 30:535-544.
17. Ellenberg SS, Temple R (2000). Placebo-controlled trials and active controlled trials in the evaluation of new treatment. Part 2: practical issues and specific cases. Ann Intern Med 133:464-470.
18. Fisher LD (1999). Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Controlled Clin Trials 20:16-39.
19. Fisher LD, Moye LA (1999). Carvedilol and the Food and Drug Administration approval process: an introduction. Controlled Clin Trials 20:1-15.
20. Fleming TR, DeMets DL (1996). Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605-613.
21. Fleming TR, Prentice RL, Pepe MS, Glidden D (1994). Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 13:955-968.
22. Food and Drug Administration Center for Biologies Evaluation and Research, Center for Device Evaluation and Research and Center for Devices and Radiologic Health (2001). Guidance for clinical trials sponsors - on the establishment and operation of clinical trials data monitoring committee and draft guidance (http://www.fda.gov/cber/gdlns/clindatmon.pdf).
23. Freedman LS, Graubard BI, Schatzkin A (1992). Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11:167-178.
24. Gait JE, Smith S, Brown SL (2000). Evaluation of safety data from controlled clinical trials: the clinical principles explained. J Drug Inform Assoc 34:273-287.
25. Hasselblad V, Kong DF (2001). Statistical methods for comparison to placebo in active-control trials. Drug Inform J 35:435-449.
26. Hauck WW, Anderson S (1999). Some issues in design and analysis of equivalence trials. J Drug Inform Assoc 33:109-118.
27. Hwang IK, Morikawa T (1999). Design issues in noninferiority/equivalence trials. J Drug Inform Assoc 33:1205-1218.
28. International Conference on Harmonization (1997a). ICH harmonised tripartite guidelines: E8: general consideration for clinical trials (http://www.ifpma.org/pdfifpma/e8.pdf).
29. International Conference on Harmonization (1997b). ICH harmonised tripartite guidelines: E9: statistical principles for clinical trials (http://www.ifpma.org/pdfifpma/e9.pdf).
30. International Conference on Harmonization (1997c). ICH harmonised tripartite guidelines: E10: choice of control group in clinical trials (http://www.ifpma.org/pdfifpma/e10.pdf).
31. Kieser M, Friede T (2000). Blinded sample size re-estimation in multi-armed clinical trials. J Drug Inform Assoc 34:455-460.
32. Koch GG (2000). Alpha calculus in a clinical trial: consideration and commentary for the new millennium (discussion). Stat Med 19:781-784.
33. Lachin JM (2000). Statistical considerations in the intent-to-treat principle. Controlled Clin Trials 21:167-189.
34. Moye LA (1999). End-point interpretation in clinical trials: the case for discipline. Controlled Clin Trials 20:40-49.
35. Moye LA (2000). Alpha calculus in a clinical trial: consideration and commentary for the new millennium. Stat Med 19:767-789.
36. Myers WR (2000). Handling missing data in clinical trials: an overview. J Drug Inform Assoc 34:525-533.
37. NIH (National Institutes of Health) Consensus Development Conference (2001). Statement on diagnosis and management of dental caries throughout life, March 26-28, 2001. More information at http://consensus.nih.gov/cons/115/ 115_statement.pdf.
38. O'Brien PC, Fleming TR (1979). A multiple testing procedure for clinical trials. Biometrics 35:549-556.
39. O'Neill RT (2000). Alpha calculus in clinical trials: considerations and commentary for the new millennium (commentary). Stat Med 19:785-793.
40. Prentice RL (1989). Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8:431-440.
41. Schafer JL (1999). Multiple imputation: a primer. Stat Methods Med Res 8:3-15.
42. Shih WJ, Quan H (1997). Testing for treatment differences with dropouts present in clinical trials - a composite approach. Stat Med 16:1225-1239.
43. Siddiqui O, Ali MW (1998). A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts. J Biopharmaceut Stat 8:545-563.
44. Temple RJ (1995). A regulatory authority's opinion about surrogate endpoints. In: Clinical measurement in drug evaluation. Nimmo WS, Tucker GT, editors. New York: Wiley.
45. Temple R, Ellenberg SS (2000). Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 133:455-463.
46. Verbeke G, LeSaffre E, Spiessens B (2001). The practical use of different strategies to handle dropouts in longitudinal studies. J Drug Inform Assoc 35:419-434.
47. Wittes J, Lakatos E, Probstfeld J (1989). Surrogate endpoints in clinical trials: cardiovascular disease. Stat Med 8:415-425.